Last reviewed · How we verify
Prevenar (Wyeth)
Prevenar is a pneumococcal conjugate vaccine that stimulates the immune system to produce antibodies against Streptococcus pneumoniae serotypes.
Prevenar is a pneumococcal conjugate vaccine that stimulates the immune system to produce antibodies against Streptococcus pneumoniae serotypes. Used for Prevention of invasive pneumococcal disease in infants and children, Prevention of pneumococcal pneumonia in adults.
At a glance
| Generic name | Prevenar (Wyeth) |
|---|---|
| Also known as | Pneumococcal conjugate vaccine |
| Sponsor | GlaxoSmithKline |
| Drug class | Pneumococcal conjugate vaccine |
| Target | Streptococcus pneumoniae polysaccharide antigens |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Prevenar contains polysaccharide antigens from multiple serotypes of S. pneumoniae conjugated to a protein carrier, which enhances immunogenicity and promotes T-cell dependent immune responses. The vaccine primes both humoral and cellular immunity to prevent invasive pneumococcal disease and pneumococcal pneumonia caused by the included serotypes.
Approved indications
- Prevention of invasive pneumococcal disease in infants and children
- Prevention of pneumococcal pneumonia in adults
Common side effects
- Injection site erythema
- Injection site swelling
- Fever
- Irritability
- Drowsiness
Key clinical trials
- Safety Study of Two Vaccine Strategies in Patients With Systemic Lupus Erythematosus (PHASE2, PHASE3)
- Vaccination With GSK 1024850A in Children Primed With GSK 1024850A & Boosted With Pneumovax 23™ (PHASE3)
- A Phase III Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants (PHASE3)
- Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines (PHASE3)
- Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants (PHASE1, PHASE2)
- Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines (PHASE3)
- Booster Vaccination Study With a Pneumococcal Vaccine in Children Primed With the Same Vaccine (PHASE3)
- Immune Response & Safety of a Hepatitis A Vaccine Given Together With a Pneumococcal Vaccine in Healthy Children 15 m of Age (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prevenar (Wyeth) CI brief — competitive landscape report
- Prevenar (Wyeth) updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI